Over the course of the projection period, the market for ocular inflammation therapy is anticipated to grow as a result of key market participants receiving regulatory approval for their product. For instance, Santen Canada Inc., a division of Santen Pharmaceutical Co., Ltd., stated that Health Canada, a government agency, has approved Cationorm Plus on October 6, 2022. A synthetic tear called Cationorm Plus restores moisture to the eye to treat dry eye and ocular allergy problems permanently.
Over the projection period, a high prevalence of rheumatoid arthritis is also anticipated to support market expansion for treatments for ocular inflammation. For instance, the age-standardized point prevalence and annual incidence rates of rheumatoid arthritis in 2017 were 246.6 and 14.9, respectively, up 7.4% and 8.2% from 1990, according to the study “Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017”, which was published in the journal Annals of the Rheumatic Diseases in November 2019. Rheumatoid arthritis causes inflammation in the sclera, the white portion of the eye, which causes pain and redness.
Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/5362
Over the projected period, the coronavirus disease (COVID-19) pandemic is anticipated to restrain the expansion of the worldwide eye inflammation therapy market. The World Health Organization (WHO) Weekly epidemiological update on COVID-19 reports that from September 26 to October 2, 2022, there were 6% fewer new cases. As a result, 6.5 million fatalities and 615 million confirmed cases have been reported globally as of October 2, 2022.
The COVID-19 pandemic presented the health care sectors with significant obstacles in the manufacturing, distribution, and supply of medical supplies, impeding their ability to expand. For instance, the National Center for Biotechnology Information reported on May 6, 2021, that the global lockdown had a negative impact on the supply of healthcare products and the manufacturing industries, which is anticipated to restrain the growth of the market for eye inflammation treatments globally.
Over the forecast period, it is anticipated that rising eye illness prevalence in the nation will fuel market expansion for eye inflammation. For instance, when compared to the global incidence of dry eye illness, India’s prevalence of the condition rose to 54.3% in 2017, according to statistics released in February 2018 by the National Institute of Health, U.S. The eye inflammation treatment market is anticipated to develop due to the rising prevalence of dry eye illness.
A 5.8% CAGR is anticipated for the global market for treating eye inflammation from 2023 to 2030, driven by expansion in promising regions, particularly Europe.
Over the projected period, the global market for eye inflammation treatment is anticipated to develop as a result of product approvals by regulatory agencies for the treatment of ocular inflammation. For instance, on June 23, 2022, the pharmaceutical company Ocumension Therapeutics announced that the National Pharmaceutical Administration had approved the New Drug Application (NDA) for the product, YUTIO in the company’s pipeline, OT-401, a sterile non-bioerodible intravitreal implant, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Bausch Health Companies Inc., Alcon Laboratories Inc., Mylan N.V., Merck & Co. Inc., Macleods Pharmaceuticals Ltd., Alimera Sciences, Inc., Pfizer Inc., AbbVie Inc., Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Akron Pharma Inc., Amgen Inc., and Intas Pharmaceuticals Ltd. are significant market participants.
Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/5362
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Eye Inflammation Treatment Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: Eye Inflammation Treatment Industry Impact
Chapter 2 Global Eye Inflammation Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Eye Inflammation Treatment (Volume and Value) by Type
2.3 Global Eye Inflammation Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Eye Inflammation Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Eye Inflammation Treatment Market Analysis
Chapter 6 East Asia Eye Inflammation Treatment Market Analysis
Chapter 7 Europe Eye Inflammation Treatment Market Analysis
Chapter 8 South Asia Eye Inflammation Treatment Market Analysis
Chapter 9 Southeast Asia Eye Inflammation Treatment Market Analysis
Chapter 10 Middle East Eye Inflammation Treatment Market Analysis
Chapter 11 Africa Eye Inflammation Treatment Market Analysis
Chapter 12 Oceania Eye Inflammation Treatment Market Analysis
Chapter 13 South America Eye Inflammation Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Eye Inflammation Treatment Business
Chapter 15 Global Eye Inflammation Treatment Market Forecast (2023-2030)
Chapter 16 Conclusions
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/5362
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027